Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1380380 | 0.85 | EPHX2 (0.38) | EPHX2 | |
| SCHEMBL28947181 | 0.81 | EPHX2 (0.43) | LMNAHTR6EPHX2 | |
| SCHEMBL20599577 | 0.79 | CHRNB2 (0.30) | — | |
| SCHEMBL1161139 | 0.76 | KDM4E (0.48) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL9936711 | 0.76 | KDM4E (0.48) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL20535845 | 0.76 | ABL1 (0.38) | TSHREPHX2 | |
| SCHEMBL16057051 | 0.76 | TSHR (0.48) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL4193315 | 0.76 | SMYD3 (0.39) | SMYD3BRD4HTR6MAPT | |
| Hydrochloric Acid SCHEMBL189985 | 0.74 | TSHR (0.47) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| Hydrochloric Acid SCHEMBL4905850 | 0.74 | TSHR (0.47) | LMNACYP3A4GABRA1TSHRGABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| CN-101500569-A | HIF hydroxylase inhibitors for treatment of anemia of cancer | FIBROGEN INC (US) | 2009-08-05 | — | — | CN | disclosed |
| CN-101490041-A | 2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | CN | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | LMNA 2945/4885CYP3A4 2161/4885GABRA1 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.